Lack of impact of hepatitis C virus infection on graft survival after kidney transplantation--a Portuguese single-center experience

Transplant Proc. 2015 May;47(4):926-32. doi: 10.1016/j.transproceed.2015.03.010.

Abstract

Background: Hepatitis C virus infection (HCV) is a common problem among kidney transplant (KT) recipients. The long-term burden of HCV infection on graft survival after kidney transplantation is controversial.

Methods: We performed a retrospective study including all renal transplant recipients with HCV infection (n = 34) compared with a control group (n = 80). The prevalence of HCV infection was 2.7%. The median follow-up period was 134 months (11 years). Graft survival and associated risk factors were assessed by means of Cox proportional hazard analysis.

Results: We found that HCV-positive patients remained on dialysis for longer periods (P = .001) and received transplants at a younger age (P = .03). Actuarial graft survival rates at 1, 5, and 10 years after KT were, respectively, 94.1%, 78.1%, and 66.9%, in the HCV-positive group and 94.9%, 89.1%, and 80.4% in the HCV-negative group. Graft survival did not differ significantly between groups (P = .154). A higher incidence of major cardiovascular disease among HCV-positive patients (P = .004) was noted. Multivariate analysis showed that HCV infection was not an important risk factor for graft loss (adjusted hazard ratio, 2.810; 95% confidence interval, 0.925-8.541; P = .069). Among the HCV-positive population, immunosuppression with cyclosporine or azathioprine conveyed better graft survival.

Conclusions: Our findings suggest that the long-term impact of HCV infection on graft survival after KT is not significant. KT remains a safe and effective modality of renal replacement in HCV-infected patients with end-stage renal disease.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Azathioprine / therapeutic use
  • Cardiovascular Diseases
  • Case-Control Studies
  • Cyclosporine / therapeutic use
  • Female
  • Graft Rejection / prevention & control
  • Graft Survival*
  • Hepatitis C, Chronic / complications*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / surgery*
  • Kidney Failure, Chronic / therapy
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Portugal
  • Proportional Hazards Models
  • Renal Dialysis / statistics & numerical data
  • Retrospective Studies
  • Risk Factors
  • Survival Rate
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Azathioprine